Published in Cytometry B Clin Cytom on July 01, 2010
EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes. Leukemia (2012) 1.93
Flow cytometric differentiation of abnormal and normal plasma cells in the bone marrow in patients with multiple myeloma and its precursor diseases. Leuk Res (2013) 1.72
New criteria for response assessment: role of minimal residual disease in multiple myeloma. Blood (2015) 1.33
Immunophenotyping in multiple myeloma and related plasma cell disorders. Best Pract Res Clin Haematol (2010) 1.08
Association of response endpoints with survival outcomes in multiple myeloma. Leukemia (2013) 1.08
Immunoglobulin heavy/light chain ratios improve paraprotein detection and monitoring, identify residual disease and correlate with survival in multiple myeloma patients. Leukemia (2012) 1.08
EuroFlow: Resetting leukemia and lymphoma immunophenotyping. Basis for companion diagnostics and personalized medicine. Leukemia (2012) 0.98
Cytogenetic profiles in multiple myeloma and monoclonal gammopathy of undetermined significance: a study in highly purified aberrant plasma cells. Haematologica (2012) 0.93
Immunophenotype of normal and myelomatous plasma-cell subsets. Front Immunol (2014) 0.90
Expression of myeloid antigen in neoplastic plasma cells is related to adverse prognosis in patients with multiple myeloma. Biomed Res Int (2014) 0.90
Flow cytometry method as a diagnostic tool for pleural fluid involvement in a patient with multiple myeloma. Mediterr J Hematol Infect Dis (2012) 0.87
Deep Response in Multiple Myeloma: A Critical Review. Biomed Res Int (2015) 0.84
Immunophenotypic characterization and quantification of neoplastic bone marrow plasma cells by multiparametric flow cytometry and its clinical significance in Korean myeloma patients. J Korean Med Sci (2013) 0.82
Differential effects of lenalidomide during plasma cell differentiation. Oncotarget (2016) 0.82
Residual malignant and normal plasma cells shortly after high dose melphalan and stem cell transplantation. Highlight of a putative therapeutic window in Multiple Myeloma? Oncotarget (2012) 0.80
Risk stratification in myeloma by detection of circulating plasma cells prior to autologous stem cell transplantation in the novel agent era. Blood Cancer J (2016) 0.80
Bendamustine, bortezomib and prednisone for the treatment of patients with newly diagnosed multiple myeloma: results of a prospective phase 2 Spanish/PETHEMA trial. Haematologica (2015) 0.79
Flow cytometric detection of the classical hodgkin lymphoma: clinical and research applications. Adv Hematol (2010) 0.77
Massive parallel IGHV gene sequencing reveals a germinal center pathway in origins of human multiple myeloma. Oncotarget (2015) 0.77
Flow cytometry remission by Ig light chains ratio is a powerful marker of outcome in multiple myeloma after tandem autologous transplant: a real-life study. J Exp Clin Cancer Res (2016) 0.76
Evolving Paradigms in the Management of Multiple Myeloma: Novel Agents and Targeted Therapies. Rare Cancers Ther (2015) 0.75
Clinical impact of immunophenotypic remission after allogeneic hematopoietic cell transplantation in multiple myeloma. Bone Marrow Transplant (2015) 0.75
Correlation between CD117+ myeloma plasma cells and hematopoietic progenitor cells in different categories of patients. Immun Ageing (2015) 0.75
Flow cytometry-based immunophenotypic analysis of primary systemic light chain amyloidosis. Oncol Lett (2017) 0.75
Flow Cytometry in Diagnosis of Myelomatous Pleural Effusion: A Case Report. Indian J Hematol Blood Transfus (2015) 0.75
Differentiation stage of myeloma plasma cells: biological and clinical significance. Leukemia (2016) 0.75
Clinical Relevance of Multicolour Flow Cytometry in Plasma Cell Disorders. Indian J Hematol Blood Transfus (2017) 0.75
The Prognostic Significance of Polyclonal Bone Marrow Plasma Cells in Patients with Relapsing Multiple Myeloma. Am J Hematol (2017) 0.75
Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders. Haematologica (2008) 2.99
Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: Consensus statements and report from a working conference. Leuk Res (2007) 2.97
Minimal residual disease monitoring in multiple myeloma: a comparison between allelic-specific oligonucleotide real-time quantitative polymerase chain reaction and flow cytometry. Haematologica (2005) 2.87
Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation. Blood (2008) 2.74
Clinical benefit associated with idiotypic vaccination in patients with follicular lymphoma. J Natl Cancer Inst (2006) 2.69
Mixed-phenotype acute leukemia: clinical and laboratory features and outcome in 100 patients defined according to the WHO 2008 classification. Blood (2011) 2.14
Comparison of immunofixation, serum free light chain, and immunophenotyping for response evaluation and prognostication in multiple myeloma. J Clin Oncol (2011) 1.78
The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance. Cancer Res (2006) 1.67
Zinc-finger transcription factor Slug contributes to the function of the stem cell factor c-kit signaling pathway. Blood (2002) 1.64
Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: a consensus proposal. Int Arch Allergy Immunol (2011) 1.63
Expanded cells in monoclonal TCR-alphabeta+/CD4+/NKa+/CD8-/+dim T-LGL lymphocytosis recognize hCMV antigens. Blood (2008) 1.61
Circulating human B and plasma cells. Age-associated changes in counts and detailed characterization of circulating normal CD138- and CD138+ plasma cells. Haematologica (2010) 1.61
Differences in anti-apoptotic and multidrug resistance phenotypes in elderly and young acute myeloid leukemia patients are related to the maturation of blast cells. Haematologica (2005) 1.56
Prognostic value of immunophenotyping in multiple myeloma: a study by the PETHEMA/GEM cooperative study groups on patients uniformly treated with high-dose therapy. J Clin Oncol (2008) 1.53
Cancer induction by restriction of oncogene expression to the stem cell compartment. EMBO J (2008) 1.52
Clinical, biological, and molecular characteristics of clonal mast cell disorders presenting with systemic mast cell activation symptoms. J Allergy Clin Immunol (2010) 1.46
Pedestrian navigation based on a waist-worn inertial sensor. Sensors (Basel) (2012) 1.46
Different subsets of peripheral blood dendritic cells show distinct phenotypic and functional abnormalities in HIV-1 infection. AIDS (2005) 1.44
Usefulness of Dynamic Urethral Resistance Relation (DURR) measurement for differential diagnosis between static and dynamic urinary obstruction in male spinal cord injury patients. Neurourol Urodyn (2012) 1.41
Standardization of flow cytometry in myelodysplastic syndromes: report from the first European LeukemiaNet working conference on flow cytometry in myelodysplastic syndromes. Haematologica (2009) 1.40
[Delayed diagnosis of HIV infections in Andalusia]. Enferm Infecc Microbiol Clin (2011) 1.40
[Surgery and blood transfusion in Jehovah's witnesses: a medical-legal review]. Cir Esp (2007) 1.39
The progression from MGUS to smoldering myeloma and eventually to multiple myeloma involves a clonal expansion of genetically abnormal plasma cells. Clin Cancer Res (2011) 1.28
Prognostic and biologic significance of chromosomal imbalances assessed by comparative genomic hybridization in multiple myeloma. Blood (2004) 1.26
The effect of mesenchymal stem cells on the viability, proliferation and differentiation of B-lymphocytes. Haematologica (2008) 1.24
Multifunctional role of Erk5 in multiple myeloma. Blood (2005) 1.22
The nature of circulating CD27+CD43+ B cells. J Exp Med (2011) 1.22
Mast cells from different molecular and prognostic subtypes of systemic mastocytosis display distinct immunophenotypes. J Allergy Clin Immunol (2010) 1.22
Identification of leptomeningeal disease in aggressive B-cell non-Hodgkin's lymphoma: improved sensitivity of flow cytometry. J Clin Oncol (2009) 1.21
Genetic abnormalities and patterns of antigenic expression in multiple myeloma. Clin Cancer Res (2005) 1.21
Conventional diagnostics in multiple myeloma. Eur J Cancer (2006) 1.20
Cancer development induced by graded expression of Snail in mice. Hum Mol Genet (2005) 1.18
Generation of flow cytometry data files with a potentially infinite number of dimensions. Cytometry A (2008) 1.16
Prognosis in adult indolent systemic mastocytosis: a long-term study of the Spanish Network on Mastocytosis in a series of 145 patients. J Allergy Clin Immunol (2009) 1.15
Detailed characterization of multiple myeloma circulating tumor cells shows unique phenotypic, cytogenetic, functional, and circadian distribution profile. Blood (2013) 1.15
CD20 positive cells are undetectable in the majority of multiple myeloma cell lines and are not associated with a cancer stem cell phenotype. Haematologica (2012) 1.14
Immunogenetics shows that not all MBL are equal: the larger the clone, the more similar to CLL. Blood (2013) 1.14
Dermoscopic features of skin lesions in patients with mastocytosis. Arch Dermatol (2011) 1.14
Relation between temperature and mortality in thirteen Spanish cities. Int J Environ Res Public Health (2010) 1.13
Risk of progression in smouldering myeloma and monoclonal gammopathies of unknown significance: comparative analysis of the evolution of monoclonal component and multiparameter flow cytometry of bone marrow plasma cells. Br J Haematol (2009) 1.13
A novel molecular mechanism involved in multiple myeloma development revealed by targeting MafB to haematopoietic progenitors. EMBO J (2012) 1.12
Bone marrow cells from myelodysplastic syndromes show altered immunophenotypic profiles that may contribute to the diagnosis and prognostic stratification of the disease: a pilot study on a series of 56 patients. Cytometry B Clin Cytom (2010) 1.12
[Diagnosis and treatment of nocturnal paroxysmal hemoglobinuria]. Med Clin (Barc) (2010) 1.10
Flow cytometry criteria for systemic mastocytosis: bone marrow mast cell counts do not always count. Am J Clin Pathol (2013) 1.10
Quantitative analysis of the expression of glycosylphosphatidylinositol-anchored proteins during the maturation of different hematopoietic cell compartments of normal bone marrow. Cytometry B Clin Cytom (2007) 1.10
Multiparameter flow cytometry quantification of bone marrow plasma cells at diagnosis provides more prognostic information than morphological assessment in myeloma patients. Haematologica (2009) 1.08
Systemic mastocytosis as a risk factor for severe Hymenoptera sting-induced anaphylaxis. J Allergy Clin Immunol (2012) 1.07
Flow cytometry in myelodysplastic syndromes: report from a working conference. Leuk Res (2007) 1.06
Minimal residual disease in adolescent (older than 14 years) and adult acute lymphoblastic leukemias: early immunophenotypic evaluation has high clinical value. Blood (2003) 1.06
TCRalphabeta+/CD4+ large granular lymphocytosis: a new clonal T-cell lymphoproliferative disorder. Am J Pathol (2003) 1.05
Methylation is an inactivating mechanism of the p16 gene in multiple myeloma associated with high plasma cell proliferation and short survival. Br J Haematol (2002) 1.05
Incidence and clinicobiologic characteristics of leukemic B-cell chronic lymphoproliferative disorders with more than one B-cell clone. Blood (2003) 1.04
Patient gender is associated with distinct patterns of chromosomal abnormalities and sex chromosome linked gene-expression profiles in meningiomas. Oncologist (2007) 1.04
Analysis of the immune system of multiple myeloma patients achieving long-term disease control by multidimensional flow cytometry. Haematologica (2012) 1.04
Incidence and characteristics of CD4(+)/HLA DRhi dendritic cell malignancies. Haematologica (2004) 1.04
Flow cytometric immunophenotyping of cerebrospinal fluid. Curr Protoc Cytom (2008) 1.03
Evaluation of multiparameter flow cytometry for the detection of breast cancer tumor cells in blood samples. Am J Clin Pathol (2005) 1.03
Imatinib mesylate (STI571) inhibits multiple myeloma cell proliferation and potentiates the effect of common antimyeloma agents. Br J Haematol (2003) 1.02
Characterization and short-term culture of cells recovered from human conjunctival epithelium by minimally invasive means. Mol Vis (2009) 1.02
Overview of clinical flow cytometry data analysis: recent advances and future challenges. Trends Biotechnol (2013) 1.01
Evaluation of the WHO criteria for the classification of patients with mastocytosis. Mod Pathol (2011) 1.01
Immunophenotypic analysis of mast cells in mastocytosis: When and how to do it. Proposals of the Spanish Network on Mastocytosis (REMA). Cytometry B Clin Cytom (2004) 1.01